Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway

• DOI: 10.1080/21655979.2021.2005988
• Publication Date: 2022-02-25T09:15:04Z
• Authors: Feng Gao; Rui Li; Pei-Feng Wei; Li Ou; Min Li; Yang Bai; Wen-Jia Luo; Zhen Fan
• Keywords: Viability assay; Everolimus

Everolimus (RAD001) is a mTOR inhibitor and widely used for the treatment of gastric cancer (GC). Evidence suggests that Rhein has anticancer effect on GC. But synergistic mechanism RAD001 combination GC not clear. The current study aims to clarify in treatment. We found dose-dependently repressed MGC-803 cell viability (50% inhibition concentration (IC50) value = 94.26 μM). (80 μM) significantly suppressed proliferation invasion. cells (IC50 45.41 nM). viability, invasion, compared administration or alone. Protein levels epithelial-mesenchymal transition (EMT)-related molecules E-cadherin, N-cadherin Vimentin expressions were affected by RAD001. facilitated apoptosis up-regulated cycle-related protein p53, cyclin-dependent kinase 4 (CDK4) cyclin D1 Moreover, phosphorylation-phosphoinositide-3-kinase (p-PI3K), p-protein B (p-AKT) p-mammalian target rapamycin (p-mTOR). Finally, decreased tumor weight volume, p-PI3K, p-Akt p-mTOR, marker Ki-67 expression, which exerted prevention